anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Investigators will implement a multisite randomized controlled trial (RCT) of a family-centered alcohol and drug prevention program for Anishinabe (Ojibwe) pre-adolescents in 3rd or 4th grade (Fall 2017) or who are age 8-10 years on June 1, 2017. to assess its efficacy for delaying and/or preventing adolescent onset of alcohol and drug use. This unique project will empirically address cultural challenges for RCTs involving AI cultures by evaluating contamination and informal diffusion in AI communities and extended families. AI values of sharing and community benefits clash with Western RCT methods of withholding benefits from control groups vs. treatment groups. Although risks of informal community dissemination and control group contamination are widely acknowledged challenges for AI RCTs, the degree to which this actually occurs and the potential impact has never been assessed. Rather, efforts are made to suppress and minimize AI values that result in informal dissemination and contamination, or the potential effects are simply ignored. This research will address these challenges by attempting to measure and control for them. The intent-to-treat study design will allow us to use question routing aimed at identifying content sharing among treatment and control adolescents and their treatment and control group parents. Moreover, the project will also use question routes to investigate potential contamination via extended family members who have contact with both the treatment and control families. Investigators will then assess potential impact of measured contamination on observed intervention effects.

At the completion of the study, Investigators will work with community research partners to develop a plan to sustain the prevention program. A sustainability plan is part of our model for developing and implementing culturally specific evidence-based prevention programs. Communities have readiness for sustainability due to familiarity and the popularity of BZDDD. We will work through community advisory boards (named Prevention Research Councils or PRCs) to place the program within schools, health services, and social services agencies. The project will leave behind comprehensive facilitator manuals in addition to a videotaped training program to facilitate ongoing training. In addition, the program has recently been adapted to a virtual program in response to COVID-19. The investigative team has a proven track record of sustainability in prior adaptions of BZDDD.
The present invention relates to medicine for treating Parkinson's disease and a processing method thereof. The medicine is prepared from 2 to 15 wt% of velvet bean or extract thereof, 6 to 13 wt% of radix polygoni multiflori preparata, 0.2 to 0.5 wt% of datura flower, 0.5 to 11.5 wt% of ginseng, 2 to 6 wt% of notoginseng, 2 to 9 wt% of angelica, 3 to 11.5 wt% of red sage root, 2 to 11.5 wt% of Fiveleaf Gynostemma Herb, 3 to 11.5 wt% of charred eucommia, 3 to 9 wt% of epimedium herb, 2 to 11.5 wt% of stiff silkorm and 2 to 9 wt% of magnolia bark. During processing, velvet bean seed is mashed and immersed by acetic acid and a diluted alcohol solution for 18 to 24 hours; immersion liquid is decompressed and concentrated by vacuum pumping equipment or corresponding equipment; concentrated liquid is dried at 50 to 60 DEG C to obtain velvet bean extract; after being pulverized, the velvet bean or the extract thereof can be prepared into preparation forms of capsules, pills, etc. according to the conventional method. The present invention corrects the practice that the DA content is increased and the Ach content is reduced in order to achieve abnormal physiological equilibrium during the present traditional PD treatment, and the DA content and the Ach content are simultaneously increased in order to achieve or trend to normal physiological equilibrium needed by human body health. In a word, the present invention solves the equilibrium problem of neurotransmitter, is also capable of exerting the protective function to the antioxidation nerve, thereby reaching the purpose of effectively treating Parkinson's disease. In addition, the present invention has the advantages of low cost of various components and small toxic and side effect.
Study participants will attend 14 visits with an integrative medicine clinician over the course of 6 months followed by a 6 month maintenance phase. The treatment modalities employed in the study will include nutrition and lifestyle recommendations.
PURPOSE: To obtain a composition containing a sensitized effector cell and an antigen molecule which contains an antibody or its conjugation product capable of binding to a target cell, and useful for exterminating the target cell selected in a mammalian host. CONSTITUTION: An effector cell (e.g. a cell-imparting T-cell) or its precursor is extracted from a man or animal host, and subsequently cultured together with both an effector cell growth factor (e.g. a lymphokine such as IL-2) and the first antigen molecule to produce a sensitized effector cell. The sensitized effector cell is combined with the second antigen molecule containing an antibody or its fragment capable of binding to the target cell and having at least one component common to the first antigen to produce the composition. When the composition is administered into a host, the second antigen molecule is localized at the target cell in the living body, and the sensitized effector cell recognizes the second antigen molecule to specifically direct the cell-impairing effect to the target cell in the host, thereby exterminating the target cell.
The present invention provides a preparation process for clindamycin phosphate injection. A method for controlling the pH value is adopted for increasing the solubility. The production process adopts a sterilization production process. A mode of combining ultrafiltration and sterilization filtration is adopted for eliminating pyrogen and sterilizing during production. Simultaneously the filling environment is a partial hundred grade in ten-thousand sterilization background, and the total sterilization operation is adopted in the production process, so that the pollution of environment and personnel is effectively prevented, and the sterility assurance level the same as that of the traditional sterilization process is obtained. In addition, the preparation process has the advantages of overcoming the defect of easy decomposition in high temperature and effectively ensuring the quality.
The present disclosure relates to humanized antibodies that specifically bind to IL-1R3 or a fragment or derivative thereof or a polypeptide that contains at least a portion of said antibody that is sufficient to confer IL-1R3 binding specificity. Said antibodies inhibit IL-1R3 induced NFkB activity. They also inhibit IL-1alpha, IL-1beta, IL-33, and/or IL-36 stimulated NFkB activity. The disclosure further relates to use of said humanized antibody in the treatment of an IL-1R3 mediated disease such as cancer. The disclosure finally encompasses a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the antibody according to the invention. The pharmaceutical composition can be used in treating a IL-1R3 mediated disease such as cancer.
The inconveniences accompanying the use of disulphiram (I, Et2N. CS. S. SC. NEt2) in sufficiently large doses to hinder the normal metabolism of alcohol in the body to pyruvic acid, CO2, etc. are overcome by coating the particles of I with up to 20 layers of material which produces its slow release in the stomach. The coating is done by repeated steepings in a soln. or suspension of the coating material with intermediate dryings. Suitable coating materials are lactose, starch, stearic acid, shellac, and film-forming polymerisates e.g. polyvinylpyrrolidone.
Olmesartan medoxomil.Tribenzor can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death. When pregnancy is detected, discontinue Tribenzor as soon as possible [see Use in specific Populations ( 8.1]. 

Hydrochlorothiazide.Thiazides cross the placental barrier and appear in cord blood. 

Adverse reactions include fetal or neonatal jaundice and thrombocytopenia [see Use in Specific Populations (8.1)].
BACKGROUND: This case report describes a 34-year-old woman who developed diplopia and strabismus 2 weeks after a vaginal delivery and epidural anesthesia.
CASE REPORT: A 34-year-old women presented to the emergency department (ED) with continued headache and new-onset diplopia after having undergone epidural anesthesia for a vaginal delivery 2 weeks prior. During that time, she underwent two blood patches, rested supine, drank additional fluids, and consumed caffeinated products for her spinal headache. When she developed double vision from a cranial nerve VI palsy, she returned to the ED. At that time, she had a third blood patch performed, and she was evaluated by a neurologist. The medical team felt the cranial nerve VI palsy was due to the downward pull of the brain and stretching of the nerve. Magnetic resonance imaging and neurosurgical closure of the dura were considered as the next steps in treatment; however, they were not performed after being declined by the patient. All symptoms were resolved over the next 3 weeks. WHY SHOULD AN EMERGENCY PHYSICIAN BE AWARE OF THIS?: This case illustrates the uncommon complication of a cranial nerve VI palsy from a persistent cerebrospinal fluid leak after a dural puncture. Emergency physicians must be aware that diplopia can be a rare presenting symptom after patients undergo a lumbar puncture. Furthermore, emergency physicians should be aware of the multiple treatment options available. Knowledge of the timeline of resolution of the diplopia is necessary to make shared decisions with our patients about escalating care.
Febuxostat is a xanthine oxidase inhibitor. The active ingredient in febuxostat tablet is 2-[3-cyano-4-(2-methylpropoxy) phenyl]-4-methylthiazole-5-carboxylic acid, with a molecular weight of 316.37. The molecular formula is C16H16N2O3S. 

The chemical structure is: 

Febuxostat is a non-hygroscopic, white to off-white colored powder that is freely soluble in dimethylformamide; soluble in dimethylsulfoxide; sparingly soluble in ethanol; slightly soluble in methanol and acetonitrile; and practically insoluble in water. The melting range is 205°C to 208°C.

Each febuxostat tablet intended for oral administration contains 40 mg and 80 mg of febuxostat. In addition, each tablet contains the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, hypromellose, lactose monohydrate, microcrystalline cellulose, polyethylene glycol, povidone, sodium stearyl fumarate, talc and titanium dioxide.
All patients receive placebo for 7 days as part of the run-in period. Patients being treated with tamoxifen were randomized to treatment arm I and received 40 gm soy protein and 90 mg isoflavones daily for 12 weeks.
This study will determine the effectiveness of two different concentrations of nitrous oxide for reducing the pain of intranasal midazolam when given for subjects already planned for moderate sedation for completion of dental procedures in the pediatric dental clinic. Moderate dental sedation is useful because it helps relieve anxiety and make the dental procedure less memorable and more comfortable for the patient. Sedation appointments typically go smoothly when the patient is calm rather than when the patient is upset. Giving midazolam through the nose can be painful and the dental provider risks upsetting a patient and causing the sedation appointment to fail. Therefore, the goal of this study is to test whether nitrous oxide administration is effective in reducing the pain from intranasal midazolam administration. The effectiveness will be measured by the primary outcome of heart rate pre- and post- midazolam administration for the two randomly assigned study arms. The first study arm will be given 30% nitrous/70% oxygen and the second study arm will be given 70% nitrous/30% oxygen prior to the midazolam administration. The secondary outcome will compare subject, dental provider, and the parent/guardian answers to questions regarding the subject's experience pre- and post- midazolam administration. The investigators hypothesize lower changes in heart rate and less pain reported following midazolam administration in subjects given 70% nitrous oxide.
A wristwatch device includes a smartwatch having a digital display screen. The watch device also includes biometric sensors and proximity sensors. Furthermore, the watch device is configured to determine the proximity of a person to the watch wearer and display an indication that corresponds to that person's body temperature. Additionally, the wristwatch device may also serve as a panic button which will alert a user when their vital signs and temperature changes rapidly. The system will record a user's vitals and temperatures every hour. In the event of a panic situation, the system will automatically screenshot and record the user's latest temperature and vitals. This information will may be linked to other individuals such as family members.
Patients will randomly divide into two groups. A common exercise program was applied to both groups during 15 sessions. Manual therapy techniques will apply to the manual therapy group in addition to exercise practices. Patients will evaluate in terms of functional status, pain, range of motion, muscle strength and health-related quality before and after 5 weeks of treatment. Also, patient's satisfaction from treatment will evaluate at the 5th week of the treatment. DASH and ASES forms for functional status, VAS for pain, digital goniometer for range of motion, manual muscle test for muscle strength, SF-12 for health-related quality of life, and Global Rating of Change (GRC) Scale for patient satisfaction will be used as evaluation criteria.
Experimental Group 01: usual care + topical application of the gel recutita chamomile. Such intervention will be characterized by topical application of the gel C. recutita, concomitantly to the initiation of radiotherapy, should be applied on the irradiated three times daily throughout the period of realization of radiotherapy sessions area, and nursing consultations with equipment instructional (usual care).
PROBLEM TO BE SOLVED: To obtain a bone amount increasing composition having inhibitory action on osteoporosis, by including an extract of Wasabia japonica. SOLUTION: This composition comprises an extract of Wasabia japonica as an active ingredient. The extracted component is obtained by adding 0-80% aqueous solution of ethanol to the whole plant (leaves, stalks or roots) of Wasabia japonica or its stalks, grinding the whole plant, shaking the ground material with a known solvent such as ethyl ether or acetonitrile and collecting its water-soluble component. A preparation containing the extract of Wasabia japonica as an active ingredient is useful for increasing a bone amount. A dose is 0.1-1,000 mg/kg weight, preferably 1-100 mg/kg weight calculated as the extract of Wasabia japonic (dried weight) daily. Since the extract of Wasabia japonic of long food history is used as the active ingredient, the composition is safe.  Since the extract can be daily taken for the sake of prevention from a young age, it can protect the quality of life of individual in one's old age and contribute to reduction in a health care cost of an aging society.
BACKGROUND: Frailty has been associated with poor outcomes and higher costs after primary total hip arthroplasty. However, frailty has not been studied in relation to outcomes after revision total hip arthroplasty (rTHA). This study examined the relationship between the Hospital Frailty Risk Score (HFRS), postoperative outcomes, and cost profiles following rTHA.
METHODS: In this retrospective cohort study, we identified patients who underwent rTHA from January 2017 to November 2019 in the Nationwide Readmission Database. The 3 most frequently reported diagnosis codes for rTHA were then selected: dislocation; mechanical loosening; and infection. We calculated the HFRS for each patient to determine frailty status. We compared 30-day readmission rate, length of stay, and hospitalization cost between frail and nonfrail patients, using multivariate logistic and negative binomial regressions to adjust for covariates. We identified 36,243 total patients who underwent rTHA. Overall, 15,448 patients had a revision for dislocation, 11,062 for mechanical loosening, and 9,733 for infection.
RESULTS: Compared to nonfrail patients, frail patients had higher rates of 30-day readmission, longer length of stay, and higher hospitalization cost. Frail patients had significantly higher rates of 30-day complication and 30-day reoperation.
CONCLUSIONS: Frailty, measured using HFRS, is associated with increased postoperative complications and costs after rTHA. The HFRS has the ability to efficiently identify frail patients at-risk for perioperative complications enabling care teams to better focus optimization interventions on this patient cohort.
Participants randomized to this group will receive active tDCS 3 times a week for approximately 3 months and then weekly for 3 months. After completing baseline procedures they will be trained how to apply the tDCS device themselves. The first 3-6 treatments will be completed at the hospital to ensure proper and safe application. Prior to taking the tDCS device home, they will pass the self-application scale adequately 3 times. Each treatment session lasts 30 minutes, during which, they will engage in mindfulness meditation.
Heart failure, irrespective of its etiology may be viewed as a progressive disorder initiated by a different events and sustained by a multifaceted pathophysiological mechanisms. Regardless of the nature of the initiating events and optimized therapy used, loss of functioning cardiac myocytes developed and the disease progressed. One potential explanation for such progression is that not all pathological mechanisms underlying the disease are antagonized enough by currently used therapeutic strategy. Accordingly, impaired myocardial perfusion secondary to microvascular dysfunction has been postulated to play a major role in the progression of heart failure despite standard therapy for heart failure. It has been hypothesized that diffuse subendocardial ischemia due to altered coronary physiology may contribute to the global cardiac dysfunction seen in heart failure patients. Accordingly, coronary endothelial dysfunction at the microvascular and epicardial level in patients with acute-onset idiopathic dilated cardiomyopathy and chronic congestive heart failure has been reported. Thus, taking all mentioned above into account, the improvement in endothelial function and diminishing of subendocardial ischemia with calcium antagonists may be promising in terms of using these drugs for therapy of patients with stable chronic heart failure. The previous randomized study (5) and our long-term pilot study support this point of view.
This invention provides a novel immunogenic composition and vaccine, process es for producing them and methods for immunization against infections and disease caused by group A Streptococci. The compositi ons include group A streptococcal polysaccharide covalen tly linked to protein or liposomes to form immunogenic conjugates. The method of  immunization for this invention comprises administering  to an individual an immunogenic amount of group A polysaccharide. The group A p olysaccharide may be administered as a vaccine either on its own, conjugated to proteins or conjugated to liposomes. Additionally, th e group A polysaccharides may be associated with an adju vant. This invention is particularly useful for providing both active and passive immunogenic protection for those populations most at ris k of contracting group A Streptococcal infections and disease namely adults, preg nant women and in particular infants and children.
PURPOSE:To provide a shrunk hair-correcting agent permitting to uniformly apply the shrunk hair-correcting agent to shrunk hair under a relatively mild condition, reducing the damage of the hair, and capable of giving an excellent correcting treatment to the shrunk hair. CONSTITUTION:A small amount of inorganic fine particle powder (e.g. talc, mica, zeolite or ceramic powder) or organic polymer fine particle powder (e.g. silk powder, silicone powder, nylon powder or polyethylene powder) is added to a shrunk hair-correcting agent usually comprising the first agent containing a reducing agent and an alkali agent and the second agent containing an oxidant. The fine particles have particle diameters of 0.05-100mum, preferably 0.1-10mum. The shrunk hair-correcting agent has good coatability on the hair, can be applied in an easy operation, reduces the damage of the hair and gives an extremely good finishing result.
Only parent caregivers of children with eczema will attend the six sessions. Each session consists of teaching in the first 2.5 hours and Q\&A in the final 0.5 hour. The children group will simultaneously attend a group activity class in a separate room for 3 hours.
The present invention discloses a preparation comprising ginseng and aconite, which is characterized in that the preparation is prepared with the following method: ginseng of 50 to 200 parts by weight and aconite of 100 to 400 parts by weight are added with ethanol of 60 to 80% to be extracted for 2 to 3 times. In each time, the dosage of ethanol is 4 to 8 times of that of the medicinal materials, and the extraction lasts for 1 to 2 hours. The extracting solutions are merged. The ethanol is recovered until the solution has no taste of ethanol, and an extracting solution comprising ginseng and aconite is obtained. The extracting solution comprising ginseng and aconite is filtered, and the filtrate goes through macroporous resin. Firstly, water of which the amount is 4 to 6 times, or ethanol of which the concentration is below 20% is used to elute the extracting solution, and the eluent is abandoned or adopted. Secondly, 1 to 10 times of ethanol of 50 to 80% is added to elute the extracting solution, and the eluent is collected. Finally, the ethanol is recovered under a pressure reduction condition until the solution has no ethanol taste, and a purified combined extracting solution comprising ginseng and aconite is obtained, or a combined extracting substance comprising ginseng and aconite is obtained after desiccation. The extracting solution or the extracting substance is added with supplementary materials, and is prepared into either preparation among a capsule, an oral medicinal solution, a drop pill, a spray preparation, a granular preparation, an injection, a power injection, a lyophiled power injection, an infusion solution, an injection with high concentration, a troche used for inoculability, a slow release microcapsule and a quick release drop pill. The present invention has advanced preparation technology, stable controllable quality, and outstanding curative effect.
The Control Group formed by 30 subjects will be administered a training program consisting of three types of exercises, taking into account: stability and lumbopelvic motor control, strengthening and stretching of the lumbar muscles, exactly the same as the Experimental Group. With a duration of 20 minutes. 2 weekly sessions will be held for 4 weeks, distributed as follows: Monday and Wednesday or Tuesday and Thursday with a total of 8 treatment sessions.